Source document

Loading document…
KPIsSections13
Headline metrics
RevenueGREEN$365.69B+6.6% YoY
Gross marginGREEN25.7%
Net incomeGREEN$11.70B+1.6% YoY
Net marginGREEN3.2%
Operating marginYELLOW4.6%
Red flags1 orange
Liquidity1
ORANGE
Current ratio 0.77current_ratio_low
Current assets are below current liabilities — short-term liquidity pressure.
Income Statement
Income Statement
MetricValueFlag
Revenue$365.69BGREEN
Revenue (quarter)$187.94BGREEN
Gross Margin25.7%GREEN
Operating Margin4.6%YELLOW
Net Margin3.2%GREEN
Net Income$11.70BGREEN
EPS (diluted)$1.46GREEN
Balance Sheet
Balance Sheet
MetricValueFlag
Cash$11.53BGREEN
Broad Liquidity$11.53BGREEN
Current Ratio0.77GREEN
Total Assets$293.91BGREEN
Total Equity$98.24BGREEN
Debt/Equity0.37GREEN
Cash Flow
Cash Flow
MetricValueFlag
Operating CF$19.71BGREEN
Cash Conversion (CFO/Rev)0.05GREEN
Free Cash Flow$5.53BGREEN

Sections in this filing

Financial Statements (unaudited)

We discuss certain legal proceedings in Part I of this Quarterly Report on Form 10-Q under the caption "Item 1. Financial Statements," in Note 5 to our Condensed Consolidated Financial Statements, which is captioned "Contingencies," under the sub-caption "Legal Proceedings." We refer you to that discussion for important information concerning those legal proceedings, including the basis for such actions and, where known, the relief sought. We provide the following additional information concerning those legal proceedings, including the name of the lawsuit, the court in which the lawsuit is pending, and the date on which the petition commencing the lawsuit or appeal was filed, in addition to disclosure of certain other legal matters. Opioid-Related Litigation: In re National Prescription Opiate Litigation (MDL No. 2804) (the "MDL") is pending in the U.S. District Court for the Northern District of Ohio and includes approximately 118 cases with claims against the Company as of August 21, 2026. In addition, the following 15 other opioid-related cases against the Company and its subsidiaries were pending in U.S. state and federal courts and Canadian courts as of August 21, 2026: Plumbers' Local Union No. 690 Industry Funds, et al. v. Purdue Pharma L.P., et al., Pa. Ct. Com. Pl., Philadelphia Cty., 7/27/26; Baby Doe 1, et al. v. Allergan Finances, LLC, et al., U.S. Dist. Ct., E.D. Tenn., 4/29/25; Marshall Cty. Bd. of Educ., et al. v. Cephalon, Inc., et al., U.S. Dist. Ct., N.D. W. Va., 10/28/24; Reiner v. CVS Pharm., Inc., et al., Nev. 5th Jud. Dist. Ct., Nye Cty., 2/26/24; Chaney v. CVS Pharm., Inc., et al., Ky. Cir. Ct., Perry Cty., 12/11/23; City of Grande Prairie, et al. v. Apotex Inc., et al., Alta. King's Bench Ct., Calgary Jud. Ctr., 4/27/23; Lac La Ronge Indian Band, et al. v. Apotex Inc., et al., Sask. King's Bench Ct., Prince Albert Jud. Ctr., 3/17/23; Commonwealth of Pennsylvania ex rel. Allegheny Cty. Dist. Att'y Stephen A. Zappala, Jr. v. CVS Ind., LLC, et al., Pa. Ct. Com. Pl., Delaware Cty., 8/8/22; Baby Doe, et al., ex rel. Their Guardian Ad Litem v. Endo Health Sols., Inc., et al., U.S. Dist. Ct., M.D. Tenn., 8/3/22; Paynter ex rel. Minor Child(ren) Z.N.B. v. McKesson Corp., et al., W. Va. Cir. Ct., Kanawha Cty., 3/28/22, appealed to W. Va. Sup. Ct., 2/28/25; Blankenship ex rel. Minor Child Z.D.B. v. McKesson Corp., et al., W. Va. Cir. Ct., Kanaw